148 related articles for article (PubMed ID: 20452134)
1. Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab.
Goyal S; Rao MS; Khan A; Huzzy L; Green C; Haffty BG
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):408-13. PubMed ID: 20452134
[TBL] [Abstract][Full Text] [Related]
2. Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.
Pernin V; Belin L; Cottu P; Bontemps P; Lemanski C; De La Lande B; Baumann P; Missohou F; Levy C; Peignaux K; Reynaud-Bougnoux A; Denis F; Gobillion A; Bollet M; Vago NA; Dendale R; Campana F; Fourquet A; Kirova YM
Br J Radiol; 2015 Apr; 88(1048):20140800. PubMed ID: 25645108
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.
Pernin V; Belin L; Cottu P; Bontemps P; Lemanski C; De La Lande B; Baumann P; Missohou F; Levy C; Peignaux K; Bougnoux P; Denis F; Bollet M; Dendale R; Vago NA; Campana F; Fourquet A; Kirova YM
Breast; 2014 Dec; 23(6):816-20. PubMed ID: 25260760
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
Burstein HJ; Bellon JR; Galper S; Lu HM; Kuter I; Taghian AG; Wong J; Gelman R; Bunnell CA; Parker LM; Garber JE; Winer EP; Harris JR; Powell SN
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):496-504. PubMed ID: 16243442
[TBL] [Abstract][Full Text] [Related]
5. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
6. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.
Shaffer R; Tyldesley S; Rolles M; Chia S; Mohamed I
Radiother Oncol; 2009 Jan; 90(1):122-6. PubMed ID: 18976826
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
8. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer.
Marhin W; Wai E; Tyldesley S
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):483-9. PubMed ID: 17601680
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
10. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study.
Dautruche A; Belin L; Cottu P; Bontemps P; Lemanski C; de la Lande B; Baumann P; Missohou F; Lévy C; Peignaux K; Reynaud-Bougnoux A; Denis F; Gobillion A; Pernin V; Kirova Y
Cancer Radiother; 2018 May; 22(3):222-228. PubMed ID: 29650388
[TBL] [Abstract][Full Text] [Related]
11. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
[TBL] [Abstract][Full Text] [Related]
12. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
Serkies K; Jassem J
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
Horton JK; Halle J; Ferraro M; Carey L; Moore DT; Ollila D; Sartor CI
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):998-1004. PubMed ID: 19560883
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
[TBL] [Abstract][Full Text] [Related]
16. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial.
MacDonald SM; Patel SA; Hickey S; Specht M; Isakoff SJ; Gadd M; Smith BL; Yeap BY; Adams J; Delaney TF; Kooy H; Lu HM; Taghian AG
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):484-90. PubMed ID: 23523326
[TBL] [Abstract][Full Text] [Related]
17. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA; Allen HJ; Moroose RL; Chan D; Hagenstad C; Applebaum SH; Patel G; Hu EH; Ryba N; Lin LS; Wang H; Glaspy J; Slamon DJ; Kabbinavar F
Clin Breast Cancer; 2010 Aug; 10(4):307-12. PubMed ID: 20705564
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil R; Moik M; Reitsamer R; Ressler S; Stoll M; Namberger K; Menzel C; Mlineritsch B
Eur J Surg Oncol; 2009 Oct; 35(10):1048-54. PubMed ID: 19250795
[TBL] [Abstract][Full Text] [Related]
20. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
Beal K; Hudis C; Norton L; Wagman R; McCormick B
Breast J; 2005; 11(5):317-20. PubMed ID: 16174151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
